Hyperinsulinemia – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Hyperinsulinemia – Pipeline Review, H1 2020’, provides an overview of the Hyperinsulinemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hyperinsulinemia

– The report reviews pipeline therapeutics for Hyperinsulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hyperinsulinemia therapeutics and enlists all their major and minor projects

– The report assesses Hyperinsulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hyperinsulinemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hyperinsulinemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hyperinsulinemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AmideBio LLC

Crinetics Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

PegBio Co Ltd

Rezolute Inc

Seneb BioSciences Inc

Sosei Heptares

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperinsulinemia - Overview

Hyperinsulinemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperinsulinemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperinsulinemia - Companies Involved in Therapeutics Development

AmideBio LLC

Crinetics Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

PegBio Co Ltd

Rezolute Inc

Seneb BioSciences Inc

Sosei Heptares

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Hyperinsulinemia - Drug Profiles

ABG-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avexitide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-02481 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-722 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNB-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperinsulinemia - Dormant Projects

Hyperinsulinemia - Product Development Milestones

Featured News & Press Releases

Jun 10, 2020: rezolute receives Rare Pediatric Disease Designation for RZ358 phase 2b candidate for the treatment of congenital hyperinsulinism enabling eligibility for priority review voucher

Jun 01, 2020: Rezolute presents RZ358 clinical data-validated model of the pharmacokinetics and glycemic response in congenital hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting

May 28, 2020: Rezolute to present clinical data for RZ358, lead candidate in phase 2b trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting

Apr 23, 2020: U.S. FDA grants orphan drug designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism

Feb 10, 2020: Rezolute initiates Phase 2b clinical trial of lead candidate RZ358 in congenital hyperinsulinism

Jul 29, 2019: Crinetics Pharmaceuticals to receive final award of SBIR grant from NIH for congenital hyperinsulinism

Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on its drug candidate ACTH Antagonist CRN-02481 at ENDO2019

Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute

Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism

Apr 09, 2018: Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development

Mar 12, 2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018

Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)

Feb 05, 2018: Hanmi annouces FDA orphan drug designation for LAPSGlucagon Analog

Sep 06, 2017: Crinetics Pharmaceuticals awarded SBIR Grant to develop new therapeutics for congenital hyperinsulinism

Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hyperinsulinemia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Hyperinsulinemia – Pipeline by AmideBio LLC, H1 2020

Hyperinsulinemia – Pipeline by Crinetics Pharmaceuticals Inc, H1 2020

Hyperinsulinemia – Pipeline by Eiger BioPharmaceuticals Inc, H1 2020

Hyperinsulinemia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020

Hyperinsulinemia – Pipeline by PegBio Co Ltd, H1 2020

Hyperinsulinemia – Pipeline by Rezolute Inc, H1 2020

Hyperinsulinemia – Pipeline by Seneb BioSciences Inc, H1 2020

Hyperinsulinemia – Pipeline by Sosei Heptares, H1 2020

Hyperinsulinemia – Pipeline by XERIS Pharmaceuticals Inc, H1 2020

Hyperinsulinemia – Pipeline by Zealand Pharma AS, H1 2020

Hyperinsulinemia – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Hyperinsulinemia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports